RT Journal Article
SR Electronic
T1 History of coronary heart disease increases the mortality rate of COVID-19 patients: a nested case-control study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.23.20041848
DO 10.1101/2020.03.23.20041848
A1 Tian Gu
A1 Qiao Chu
A1 Zhangsheng Yu
A1 Botao Fa
A1 Anqi Li
A1 Lei Xu
A1 Yaping He
A1 Ruijun Wu
YR 2020
UL http://medrxiv.org/content/early/2020/04/03/2020.03.23.20041848.abstract
AB Background China has experienced an outbreak of a novel human coronavirus (SARS-CoV-2) since December 2019, which quickly became a worldwide pandemic in early 2020. There is limited evidence on the mortality risk effect of pre-existing comorbidities for coronavirus disease 2019 (COVID-19), which has important implications for early treatment.Objective Evaluate the risk of pre-existing comorbidities on COVID-19 mortality, and provide clinical suggestions accordingly.Method This study used a nested case-control design. A total of 94 publicly reported deaths in locations outside of Hubei Province, China, between December 18th, 2019 and March 8th, 2020 were included as cases. Each case was matched with up to three controls, based on gender and age ± 1 year old (94 cases and 181 controls). The inverse probability weighted Cox proportional hazard model was performed.Results History of comorbidities significantly increased the death risk of COVID-19: one additional pre-existing comorbidity led to an estimated 40% higher risk of death (p<0.001). The estimated mortality risk in patients with CHD was three times of those without CHD (p<0.001). The estimated 30-day survival probability for a profile patient with pre-existing CHD (65-year-old female with no other comorbidities) was 0.53 (95% CI [0.34-0.82]), while it was 0.85 (95% CI [0.79-0.91]) for those without CHD. Older age was also associated with increased death risk: every 5-year increase in age was associated with a 20% increased risk of mortality (p<0.001).Conclusion Extra care and early medical intervention are needed for patients with pre-existing comorbidities, especially CHD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the National Natural Science Foundation of China (No. 71874111), Shanghai Municipal Health Bureau Foundation (No. 201740116) and Shanghai Jiao Tong University Scientific and Technological Innovation Funds (YG2020YQ01, YG2020YQ06).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code are all available and in preparation.